Search Within

James Joseph Harding

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (48)
  2. Journal Article (41)
Groups
  1. Department of Medicine (89)
  2. Epidemiology and Biostatistics (89)
  3. Gastrointestinal Oncology Service (89)
  4. Solid Tumor Oncology Division (89)
  5. Center for Pancreatic Cancer Research (75)
  6. Biostatistics Service (63)

More Groups

People
  1. Ghassan Abou-Alfa (69)
  2. Eileen O'Reilly (46)
  3. William Jarnagin (43)
  4. Marinela Capanu (36)
  5. Joanne Chou (29)
  6. Michael Berger (29)

More People

Years
  1. 2025 (4)
  2. 2024 (16)
  3. 2023 (9)
  4. 2022 (7)
  5. 2021 (5)
  6. 2020 (9)

More Years

Publications
  1. Journal of Clinical Oncology (38)
  2. Clinical Cancer Research (8)
  3. Annals of Surgical Oncology (7)
  4. JCO Precision Oncology (6)
  5. Cancer (5)
  6. The Oncologist (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (46)
  2. American Association for Cancer Research (10)
  3. Springer (8)
  4. Wiley Blackwell (7)
  5. Oxford University Press (6)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (89)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I trial of binimetinib in combination with gemcitabine (G) and cisplatin (C) patients (pts) with untreated advanced biliary cancer (ABC)
    Meeting Abstract

    Lowery, M. A.; O'Reilly, E. M.; Harding, J. J.; Salehi, E.; Hollywood, E.; Bradley, M.; Sophos, N. A.; Ly, M.; Capanu, M.; Gerst, S. R.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Hepatocellular carcinoma (HCC) and bone metastases (Mets)
    Meeting Abstract

    Harding, J. J.; Abu Zeinah, G.; Chou, J. F.; Owen, D. H.; Ly, M.; Lowery, M. A.; O'Reilly, E. M.; Capanu, M.; Saltz, L.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • First stage results of a phase II trial of sorafenib plus doxorubicin (SD) in patients (pts) with advanced hepatocellular carcinoma (HCC) who progressed (POD) on sorafenib (S)
    Meeting Abstract

    Abou-Alfa, G. K.; Capanu, M.; Do, R. K. G.; Hollywood, E.; Ly, M.; Chou, J. F.; Lee, J. K.; Connell, L. C.; Wan, P. J.; Bradley, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Randomized phase II study of everolimus (E), leuprolide + letrozole (LL), and E + LL (ELL) in patients (pts) with unresectable fibrolamellar carcinoma (FLC)
    Meeting Abstract

    Abou-Alfa, G. K.; Mayer, R. J.; Cosgrove, D.; Capanu, M.; Choti, M. A.; Atreya, C. E.; Ang, C.; Kelley, R. K.; Do, R. K. G.; Gordan, J. D.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases
    Journal Article

    Harding, J. J.; Catalanotti, F.; Munhoz, R. R.; Cheng, D. T.; Yaqubie, A.; Kelly, N.; McDermott, G. C.; Kersellius, R.; Merghoub, T.; Lacouture, M. E.; more...
    The Oncologist (2015)

    Fulltext@MSK | Save
  • Prognostic role of C-reactive protein levels in patients with hepatocellular carcinoma undergoing sorafenib therapy
    Meeting Abstract

    Lee, J. K.; Harding, J. J.; Chou, J. F.; Capanu, M.; Saltz, L.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Embolization versus embolization and systemic therapy in patients with hepatocellular carcinoma and metastatic disease: A retrospective analysis
    Meeting Abstract

    Kim, S.; Brown, K. T.; Fong, Y. M.; Solomon, S. B.; Chou, J. F.; Capanu, M.; Harding, J. J.; O'Reilly, E. M.; Saltz, L.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Ipilimumab for patients with advanced mucosal melanoma
    Journal Article

    Postow, M. A.; Luke, J. J.; Bluth, M. J.; Ramaiya, N.; Panageas, K. S.; Lawrence, D. P.; Ibrahim, N.; Flaherty, K. T.; Sullivan, R. J.; Ott, P. A.; more...
    The Oncologist (2013)

    Fulltext@MSK | Save
  • Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3mg/kg)
    Meeting Abstract

    Postow, M. A.; Yuan, J.; Panageas, K.; Bogatch, K.; Callahan, M.; Cheng, M.; Schroeder, S. E. A.; Kendle, R. F.; Harding, J. J.; Dickson, M. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save